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This trial is registered with ClinicalTrials.gov, number NCT01472887. 
Abstract 
This phase 2, single-arm, multicenter study examined the efficacy and safety of coltuximab 
ravtansine (an anti-CD19 antibody drug conjugate) in 61 patients with histologically documented (de 
novo or transformed) relapsed or refractory diffuse large B-cell lymphoma who had previously 
received rituximab containing immuno-chemotherapy. Patients had received a median of 2.0 (range 
0–9) prior treatment regimens for diffuse large B-cell lymphoma and almost half (45.9%) had bulky 
disease (≥1 lesion >5 cm) at trial entry. Patients received coltuximab ravtansine (55 mg/m
2
) in 4 
weekly and 4 biweekly administrations until disease progression or unacceptable toxicity. 41 
patients were eligible for inclusion in the per-protocol population. The primary endpoint, overall 
response rate (International Working Group criteria) in the per-protocol population, was 18/41 
(43.9% [90% confidence interval  30.6-57.9%]). Median duration of response, progression-free 
survival and overall survival (all treated patients) were 4.7 (range 0.0–8.8) months, 4.4 (90% 
confidence interval 3.02-5.78) months, and 9.2 (90% confidence interval 6.57-12.09) months, 
respectively. Common non-hematologic adverse events included asthenia/fatigue (30%), nausea 
(23%), and diarrhea (20%). Grade 3-4 adverse events were reported in 23 patients (38%), the most 
frequent being hepatotoxicity (3%) and abdominal pain (3%). Eye disorders occurred in 15 patients 
(25%); all were grade 1-2 and none required a dose modification. Coltuximab ravtansine 
monotherapy was well tolerated and resulted in moderate clinical responses in pretreated patients 
with relapsed/refractory diffuse large B-cell lymphoma. 
ClinicalTrials.gov trial identifier: NCT01472887  
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Introduction 
Diffuse large B-cell lymphoma (DLBCL) is the most frequent form of non-Hodgkin lymphoma, 
representing approximately 30–58% of cases.
1
 The majority of cases of DLBCL occur de novo, 
although some develop from indolent lymphoma.
2
 DLBCL is subclassified as germinal center B-cell-
like (GCB) or activated B-cell-like (ABC) subtypes based on gene expression profiling. The ABC 
subtype has a worse prognosis than the GCB subtype.
3
 In addition, concurrent deregulation of MYC 
and BCL2 has been associated with poor outcomes,
4,5
 however the prognostic significance of these 
rearrangements remains controversial.
6-8
  
Standard first-line therapy for DLBCL is cyclophosphamide, hydroxydaunorubicin, vincristine, 
and prednisone, combined with rituximab (R-CHOP). Five-year overall survival (OS) in patients 
treated with this regimen is over 70%.
9,10
 Dose-adjusted etoposide, prednisone, vincristine, 
cyclophosphamide, doxorubicin, rituximab (DA-EPOCH-R), showed promise as an alternative first line 
regimen to R-CHOP in a phase 2 study, 
11
 but failed to demonstrate superior event-free or overall 
survival (OS) in a phase 3 trial, which directly compared the two regimens
12
. The majority of patients 
in the phase 3 study had good prognostic features, and therefore it is possible that DA-EPOCH-R may 
provide an advantage in patients with an adverse prognosis (such as MYC/BCL2 double-hit 
lymphoma) or rare subtypes (such as primary mediastinal lymphoma). However, the phase 3 study 
was not designed to answer this question, and R-CHOP remains the standard of care for the majority 
of unselected patients with DLBCL.
12-15
 Salvage treatment with autologous stem cell transplantation 
(ASCT) is the most effective approach at first relapse. However, it can only be offered to young, fit 
patients, and long-term survival is only 40%.
16
 There are limited treatment options with unsatisfying 
results for patients relapsing after, or ineligible for, ASCT.
17
 New therapeutic strategies are essential 
for these patients. 
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Coltuximab ravtansine (SAR3419) is an anti-CD19 monoclonal antibody conjugated to a potent 
cytotoxic maytansinoid, DM4, via an optimized, hindered, disulfide bond. The antibody selectively 
binds to the CD19 antigen present on the majority of B cells, resulting in internalization of the 
receptor–drug complex and intracellular release of DM4. DM4 is a potent inhibitor of tubulin 
polymerization and microtubule assembly, functioning by similar mechanisms to vincristine and 
vindesine.
18,19
  
Coltuximab ravtansine has been evaluated in patients with relapsed/refractory (R/R) B-cell 
non-Hodgkin lymphoma. A first-in-human phase 1 study examined several dose levels in 3-weekly 
administrations. At the maximum tolerated dose (160 mg/m
2
) few clinical responses and high levels 
of treatment-related ocular toxicity were observed.
20
 A further phase 1, dose-escalation study 
examined once-weekly dosing and a modified schedule consisting of four weekly doses followed by 
four doses given once every 2 weeks. Both schedules showed anti-lymphoma activity in 
approximately 30% of patients with either indolent or aggressive disease. The maximum tolerated 
dose was 55 mg/m
2
, and the modified dosing schedule was found to limit drug accumulation, reduce 
toxicity, and improve response rates.
19
  
To confirm the clinical benefit observed in the phase 1 setting in a population with aggressive 
lymphoma, we conducted a phase 2, open-label, multicenter study evaluating coltuximab ravtansine 
monotherapy in transplant-ineligible patients with CD19-positive, R/R DLBCL. 
Methods 
Study design 
In this phase 2, open-label, single-arm study patients received four weekly doses of intravenous (iv) 
coltuximab ravtansine 55 mg/m
2
, followed by a 1-week rest period, then biweekly doses until 
disease progression (PD), unacceptable toxicity, or discontinuation of treatment. One cycle was 4 
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weeks, except for cycle 1 (5 weeks). At the investigator’s discretion, patients received premedication 
consisting of iv diphenhydramine 50 mg and oral acetaminophen 650 mg 30-45 minutes before each 
infusion. Dose reductions were permitted (see supplementary materials).  
Patients 
Adult patients with de novo or transformed histologically confirmed DLBCL and >30% of cells 
expressing CD19 (local assessment) were enrolled. Patients had relapsed (progression ≥6 months 
after completion of last line of therapy) or refractory (progression during, or within 6 months of, a 
prior therapy) disease and had previously received standard chemotherapy (including rituximab). 
Patients with primary refractory disease (refractory to first line therapy) were ineligible. However 
some primary refractory patients were wrongly enrolled (see results). Full inclusion and exclusion 
criteria are included in the supplementary material.  
All patients provided written informed consent. The protocol and subsequent amendments 
were approved by independent ethics committees and/or institutional review boards at each center. 
The study was conducted according to the Declaration of Helsinki. 
Outcomes 
The primary endpoint was overall response rate (ORR; proportion of patients achieving a 
partial response [PR] or complete response [CR] [International Working Group criteria
21
]). Secondary 
endpoints included duration of response (DOR; time from first PR or CR until PD or death), 
progression-free survival (PFS; time from first study treatment until PD or death), OS (time from first 
study treatment until death), and safety. Assessment of biomarkers was an exploratory endpoint.  
Assessments 
Assessment of clinical response involved physical examination, bone marrow biopsy, and 
computerized tomography (CT) every 12 weeks until PD or treatment discontinuation. Positron-
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emission tomography (PET) was done at baseline and, if positive, repeated to confirm a CR. Patients 
with a negative CT but positive PET were classified as PR.  
Adverse events (AEs) were classified using National Cancer Institute Common Terminology 
Criteria for Adverse Events (v4.03). Pre-specified AEs of special interest were eye disorders, 
neuropathy, and infusion-related reactions (all drug hypersensitivity reactions and treatment-related 
AEs occurring on the day of infusion).  
Details of biomarker assessments are included in the supplementary materials. 
Statistical analysis 
The predicted beneficial ORR was ≥40%. Assuming 44 patients evaluable for response, the study had 
90% power to reject the null hypothesis of an ORR of 20% with a one-sided α=0.05. An ORR of <20% 
was considered clinically uninteresting based on available observations from coltuximab ravtansine 
and new agents in relapsed/refractory non-Hodgkin lymphoma and/or DLBCL, for which activity 
ranged between 15% and 30% in Phase 2 studies.
22-28
 The primary endpoint (ORR), was assessed in 
the per-protocol (PP) population (all treated patients who had an evaluable response assessment 
during or at the end of treatment or who died due to PD before response assessment, without any 
important protocol deviations affecting efficacy at study entry). ORR was also assessed in the 
biomarker-evaluable population (all patients with results of biomarker analysis from a fresh or 
archival sample). DOR and PFS were assessed in the PP population, and OS and safety were assessed 
in all treated patients (safety population).  
Statistical analysis of biomarkers are detailed in the supplementary materials. 
Results 
Overall, 61 patients were enrolled (20 January 2012 to 23 July 2013) and received ≥1 dose of study 
drug (safety population). Twenty patients were excluded from the PP population (Figure 1), of whom 
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16 were wrongly enrolled in the study due to misclassification of their prior treatment history.  Of 
these 16 patients, primary refractory disease was the sole important deviation at study entry in 14. 
The primary endpoint (ORR) was analyzed separately in this subgroup.  
Baseline characteristics of the safety population are summarized in Table 1. Most patients 
(50/61 patients; 82.0%) presented with DLBCL at initial diagnosis. Of those patients with 
transformed lymphoma (n=11), seven were initially diagnosed with follicular lymphoma and nine 
had received prior anticancer therapy for non-DLBCL lymphoma (six patients received ≥1 prior anti-
CD20-containing regimen).  Almost half of the patients (45.9%) had bulky disease (defined as longest 
diameter of the lesion >5 cm for at least one location). Patients had received a median of 2.0 (range 
0-9) prior treatment regimens for DLBCL, with 18 patients (29.5%) having received ≥3 prior regimens.  
Patients received a median of 3 (range 1-10) cycles of therapy (median duration of treatment 13.3 
[range 5-41] weeks). Thirty-nine of 61 treated patients (63.9%) received ≥3 treatment cycles, 
including 16 patients who received ≥6 cycles. Overall, 56 patients discontinued treatment due to: PD 
(n=47), AEs (n=6), or investigator’s decision (n=3). At the time of analysis (6 May 2014), five patients 
were continuing on therapy.  
The ORR (primary endpoint), analyzed in the PP population (n=41), was 43.9% (18/41; 90% CI 
30.6-57.9%); therefore, the null hypothesis was rejected (P<0.0001). Among the 18 responders, 6 
achieved CR (PET negative) and 12 achieved PR (PET positive [n=8] or not examined [n=4]) (Table 2). 
Seven patients (7/41; 17.1%) had stable disease, and the remaining patients (16/41; 39.0%) had 
progressive disease. Higher response rates were observed among patients with relapsed DLBCL 
(14/26; 53.8%, 90% CI 36.2-70.8%) compared with patients refractory to their last regimen (4/15; 
26.7%, 90% CI 9.7-51.1%).  A higher ORR (56.3%) was also observed in patients who received only 1 
prior therapeutic regimen (n=16). At the time of analysis, six patients with relapsed disease were still 
responding to therapy (three CRs and three PRs). 
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ORR was also assessed in 14 patients with primary refractory disease (sole important 
deviation affecting efficacy) who were excluded from the PP population. Among these patients, the 
ORR was 21.4% (3/14; 90% CI 6.1-46.6%), with the majority having PD (9/14; 64.3%) and only one 
patient achieving CR.  
Figure 2 shows the DOR in individual patients in the PP population according to initial 
responses. The median DOR was 4.7 (range 0-8.8) months. Of 18 patients who responded to 
coltuximab ravtansine treatment (PR or better), four achieved a DOR of >6 months (one of four 
patients with refractory disease and three of fourteen patients with relapsed disease). At the time of 
analysis, 34/41 patients (82.9%) in the PP population had experienced PD and the median PFS was 
4.4 (90% CI 3.02-5.78) months. Forty-one of the 61 patients in the safety population had died at the 
analysis cut-off date. Estimated median OS was 9.2 (90% CI 6.57-12.09) months (Figure 3).  
CD19 was locally assessed in all patients (n=41) during enrollment, and centrally assessed in 
37/41 PP patients (90.2%) during biomarker analysis. Overall, 35 patients had ≥30% CD19-positive 
cells (range 30-100%). Variable levels of expression were recorded, with 11, 16, and 8 samples 
having a mean intensity of 1+, 2+, and 3+, respectively. The median H-score (see supplementary 
methods) was 162 (range 0-270). There was no relationship between levels of expression of CD19 
and response; some patients with high CD19 expression had PD as their best response whereas 
some patients with lower expression experienced a PR (Supplementary Figure 1). Two patients with 
absent CD19 staining had progressive disease. For each measure of CD19 expression, the receiver-
operating characteristic curve AUC values varied between 0.42 and 0.65, indicating that none of the 
CD19 expression measures showed good predictive accuracy for distinguishing between responders 
and non-responders (Supplementary Table 1). No significant optimal cut-off point for CD19 
expression was identified. In addition, there was no apparent correlation between cell of origin 
classification or MYC/BCL2 expression and response rate (data not shown).  
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All 61 patients in the safety population (Table 3) experienced ≥1 AE, including 33/61 patients 
(54%) who experienced ≥1 treatment-related AE. Grade 3-4 AEs were reported in 23/61 patients 
(38%), the most frequent being hepatotoxicity (2/61, 3%) and abdominal pain (2/61, 3%). Serious 
AEs (SAEs) were reported in 24/61 patients (39%). Six SAEs (occurring in 3 patients) were considered 
related to treatment: hepatotoxicity (n=2), pneumonia, abdominal pain, nausea, and grade 5 febrile 
neutropenia (n=1). 
The most common grade 3-4 hematologic laboratory abnormalities were neutropenia (25%), 
lymphopenia (21%), and leucopenia (15%) (Table 3). Grade 3-4 non-hematologic laboratory 
abnormalities were rare, with elevated levels of aspartate aminotransferase, alkaline phosphatase, 
alanine aminotransferase, and creatinine each occurring in 2 patients. Grade 3-4 febrile neutropenia 
was also observed in one patient, but did not require growth factor administration. 
Eye disorders occurred in 15 patients (25%); all were grade 1-2 and none required a dose 
modification. Nineteen extracorneal eye disorders were observed in 13 patients (21.3%), with the 
first occurrence during cycle 1 (6 patients), cycle 2 (n=2), cycle 3 (n=3), cycle 7 (n=1), and cycle 9 
(n=1). Fourteen of these events had resolved at the time of data cut-off, with a median recovery 
time of 12.5d (range 1-47). One patient experienced a corneal event (grade 2 keratitis during cycle 
4), which resolved within 9d. A further two patients experienced dry eyes, occurring during cycle 1 
and resolving after 13d and 17d, respectively. Neuropathy was observed in 7 patients (11%). Five 
patients (8%) reported peripheral neuropathy (PN) occurring during cycle 1 (n=3) or cycle 2 (n=2), 
including one case of grade 3 PN (unrelated to study treatment) in a patient with a history of the 
condition. Dose modifications were not required in any of the patients with PN, although none of 
these events had resolved at the time of analysis. A further two patients presented with events 
compatible with optic neuropathy (grade 1); this diagnosis was not confirmed, but could not be 
confidently excluded. Neither of these patients required a dose modification and both events 
resolved within a median of 9d (range 4-14). Overall, infusion-related reactions occurred in 10 
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patients (16%), and were most commonly gastrointestinal in nature (nausea 10%, vomiting 3%). 
Drug hypersensitivity was observed in one patient. 
Dose modifications (dose omission, interruption, or cycle delay) due to AEs were required in 
17 patients (28%), including 9 patients (15%) who experienced a grade 3-4 AE. Nine patients (15%) 
had ≥1 cycles delayed by >3d, and 9 patients (15%) had one dose omitted. One patient (2%) required 
a dose interruption due to grade 1 hypotension, which was considered to be unrelated to treatment.  
Of eight patients (13%) who experienced AEs leading to death, seven were due to PD. The 
other patient who died developed febrile neutropenia 34d after the last dose of coltuximab 
ravtansine while receiving further anticancer therapy (gemcitabine–cisplatin); the investigator could 
not exclude the possibility that the event was due to a delayed effect of coltuximab ravtansine 
treatment. 
Discussion 
The results of this phase 2 trial indicate that treatment with coltuximab ravtansine as 
monotherapy is associated with moderate clinical responses in a proportion of DLBCL patients 
previously treated with rituximab-based chemotherapy, and has a favorable toxicity profile.  
The responses described here are numerically higher than those reported in a phase 2 study 
of coltuximab ravtansine in combination with rituximab (ORR 44% [90% CI 30.6–57.9%] versus 31% 
[80% CI 22.0–41.6%], respectively).
29
 However, patients enrolled in the combination study were 
limited to 3 cycles of treatment, whereas in the current study patients continued on therapy until 
disease progression or discontinuation due to an adverse event or investigator’s decision. 
Additionally, the patients in the combination therapy study could be described as a more refractory 
population (60% of patients had primary refractory disease), whereas the primary analysis 
population for the current study excluded patients with primary refractory disease. It should be 
noted that some patients with primary refractory disease were wrongly included in this study due to 
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a misclassification of their prior treatment history. The response rates described here are in line with 
other antibody–drug conjugates, when tested as monotherapy (44–56%)
30,31
 or in combination with 
rituximab (29–54%).
32,33
 Interestingly, the anti-CD30 antibody–drug conjugate brentuximab vedotin 
achieved an ORR of 44% among patients with R/R DLBCL, most of whom were refractory to their first 
(76%) and last (82%) line of therapy.
30
 The response rates were also similar to anti-CD19 monoclonal 
antibodies, such as MEDI-551, MOR208, and blinatumomab, currently in phase 2 development for 
DLBCL.
34-36
 In comparison, in a recent multicenter, randomized study of the aza-anthracenedione 
pixantrone in patients with aggressive B-cell lymphoma (DLBCL, transformed indolent lymphoma, or 
follicular lymphoma)
37
, the ORR was 26% (CR, 15%), with a median PFS of 5.7 months (95% CI 2.4–
6.5).  
 The response rates among patients refractory to their first or last line of therapy were 
numerically lower than those observed among the relapsed patients included in the study (21.4% 
and 26.7% versus 53.8%, respectively). However, given the limited numbers of patients in each 
group it is difficult to draw firm conclusions.  
Biomarker analysis revealed no apparent correlation between cell of origin classification or 
MYC/BCL2 expression and clinical response. In addition, none of the CD19 expression measures 
analyzed showed good predictive accuracy for distinguishing responders and non-responders, and 
no significant optimal cut-off point for CD19 expression could be identified. This lack of correlation 
between CD19 expression and efficacy is counterintuitive, but may represent an effect of coltuximab 
ravtansine on the tumor microenvironment that is important for lymphoma cell growth and 
survival.
38
 Additional ad hoc analyses would be required to investigate this further. Interestingly, 
preclinical studies have also demonstrated that low levels of CD22 or CD79B expression on target 
cells does not reduce the antitumor activities of pinatuzumab vedotin or polatuzumab vedotin, 
respectively.
39
 Similar findings have also been reported in a brentuximab vedotin phase 2 study in 
DLBCL, in which responses were not dependent on CD30 expression.
30
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Overall, coltuximab ravtansine exhibited a favorable safety profile, with the majority of the 
most common AEs reported at grade 1-2. The most frequent grade 3-4 AEs were hematologic or 
gastrointestinal in nature. No study-onset occurrences of grade 3-4 PN or ocular toxicity were 
observed, and grade 1-2 toxicities were reversible and manageable. In addition the majority of these 
events occurred during cycles 1-2 suggesting that they may result from the more intensive dosing of 
coltuximab ravtansine during the first cycle of the study, rather than drug accumulation. Indeed 
Ribrag et al.
19
 demonstrated a reduced incidence of ocular toxicities and PN with the optimized 
schedule used here versus a weekly dosing schedule. Dose modifications were required in 28% of 
patients due to AEs, approximately half of which were grade 3-4. No dose reductions were required 
during the study. SAEs considered related to study treatment were uncommon. 
In conclusion, the results of this phase 2 study indicate that the optimized dosing regimen of 
coltuximab ravtansine may have some efficacy in patients with relapsed or refractory DLBCL, 
previously treated with rituximab.  
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Table 1. Baseline characteristics (safety population; n=61) 
Variable Value, n (%) 
Median age (range), years 69 (30–88) 
Age group, years 
<65 
65–75 
≥75 
 
17 (27.9%) 
26 (42.6%) 
18 (29.5%) 
Sex 
Male 
Female 
 
31 (50.8%) 
30 (49.2%) 
Histology (investigator determined) 
De novo DLBCL 
Transformed DLBCL 
 
50 (82.0%) 
11 (18.0%) 
Cell of origin classification
* 
ABC 
GCB 
Unclassified 
 
16 (43.2%) 
17 (45.9%) 
4 (10.8%) 
ECOG performance status
† 
0 
1 
2 
 
27 (45.0%) 
26 (43.3%) 
7 (11.7%) 
Ann Arbor stage 
I 
II 
III 
IV 
 
4 (6.6%) 
11 (18.0%) 
15 (24.6%) 
31 (50.8%) 
International prognostic index score 
    Low 
    Low intermediate 
    High intermediate 
    High 
 
12 (19.7%) 
11 (18.0%) 
25 (41.0%) 
13 (21.3%) 
Lactate dehydrogenase >ULN
†
 41 (68.3%) 
Extranodal involvement 36 (59.0%) 
Bulky disease
‡
 28 (45.9%) 
Prior transplant for DLBCL 12 (19.7%) 
Disease status at study entry
§ 
Primary refractory 
 
16 (26.7%) 
21 
 
Refractory to last regimen 
Relapsed 
16 (26.7%) 
28 (46.7%) 
Number of prior regimens for DLBCL 
0 
1 
2 
3 
>3 
 
1 (1.6%) 
25 (41.0%) 
17 (27.9%) 
9 (14.8%) 
9 (14.8%) 
Prior regimen for non-DLBCL lymphoma
¶ 
9 (81.8%) 
Data are n (%) unless otherwise stated. 
ABC: activated B-cell-like; DLBCL: diffuse large B-cell lymphoma; ECOG: European Cooperative 
Oncology Group; GCB: germinal center B-cell-like; ULN: upper limit of normal. 
*n=37. 
†
n=60. 
‡
Longest diameter of lesion >5 cm for at least 1 location. 
§
n=60 (1 patient had 
received no prior regimen for DLBCL). 
¶
n=11 (patients with transformed DLBCL). 
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Table 2. Summary of best response to treatment by subgroup based on International Working 
Group criteria 
Response,  
n (%) 
All 
(n=41) 
Refractory to 
last regimen 
(n=15) 
Relapsed 
(n=26) 
Primary 
refractory 
(n=14) 
ORR 18 (43.9%) 4 (26.7%) 14 (53.8%) 3 (21.4%) 
90% CI* 30.6–57.9 9.7–51.1 36.2–70.8 6.1–46.6 
CR 
PR 
6 (14.6%) 
12 (29.3%) 
1 (6.7%) 
3 (20.0%) 
5 (19.2%) 
9 (34.6%) 
1 (7.1%) 
2 (14.3%) 
SD 7 (17.1%) 3 (20.0%) 4 (15.4%) 2 (14.3%) 
PD 16 (39.0%) 8 (53.3%) 8 (30.8%) 9 (64.3%) 
CI: confidence interval; CR: complete response; ORR: overall response rate; PD: progressive disease; 
PR: partial response; SD: stable disease 
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Table 3. AEs occurring in ≥10% of patients (safety population; n=61) 
AE, n (%) All grades Grade 3–4 Grade 5 
Any AE 61 (100%) 23 (38%) 8 (13%) 
Serious AEs 24 (39%) 14 (23%) 8 (13%) 
AE leading to dose modification*
 
17 (28%) 9 (15%) – 
AE leading to discontinuation 4 (7%) 0 – 
Non-hematologic AEs 
Asthenia/fatigue 
Nausea 
Diarrhea 
Cough 
Vomiting 
Decreased appetite 
Disease progression 
Back pain 
Abdominal pain 
Dyspnea 
Constipation 
Peripheral edema 
 
18 (30%) 
14 (23%) 
12 (20%) 
11 (18%) 
8 (13%) 
8 (13%) 
8 (13%) 
7 (11%) 
7 (11%) 
6 (10%) 
6 (10%) 
6 (10%) 
 
1 (2%) 
1 (2%) 
0 
0 
0 
0 
3 (5%) 
1 (2%) 
2 (3%) 
1 (2%) 
0 
0 
 
0 
0 
0 
0 
0 
0 
5 (8%) 
0 
0 
0 
0 
0 
Laboratory abnormalities    
Hematologic AEs
† 
Anemia 
Lymphopenia 
Leukopenia 
Thrombocytopenia 
Neutropenia 
 
53 (87%) 
41 (67%) 
39 (64%) 
35 (57%) 
32 (52%) 
 
4 (7%) 
13 (21%) 
9 (15%) 
6 (10%) 
15 (25%) 
 
– 
– 
– 
– 
– 
Hepatic and renal abnormalities 
AST 
Alkaline phosphatase‡ 
ALT 
Creatinine  
Bilirubin
 
 
37 (61%) 
26 (45%) 
27 (44%) 
19 (31%) 
9 (15%) 
 
2 (3%) 
2 (3%) 
2 (3%) 
2 (3%) 
1 (2%) 
 
– 
– 
– 
– 
– 
AE: adverse event; ALT: alanine aminotransferase; AST: aspartate aminotransferase. 
*Including dose omission, interruption, and cycle delays. 
†
Laboratory evaluations. 
‡
n=58. 
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Figure legends 
Figure 1: Inclusion of patients in the per protocol (PP) efficacy analysis 
Patients were recruited at 28 sites in the USA, Belgium, Czech Republic, Israel, Italy, Poland, Spain, 
Turkey and UK. The per protocol (PP) population consisted of all treated patients who had an 
evaluable response assessment during or at the end of the treatment protocol or who died due to 
PD before response assessment, without any important protocol deviations affecting efficacy at 
study entry. CT: computed tomography; DLBCL: diffuse large B-cell lymphoma. *Some patients met 
multiple exclusion criteria. 
†
14
 
patients had primary refractory disease as their only protocol 
deviation. 
Figure 2: Duration of response by individual patient in the PP population 
Patients with a duration of response of 0.03 months were censored to the first documentation of the 
response, in the absence of another evaluable assessment before the cut-off date. CR: complete 
response; DLBCL: diffuse large B-cell lymphoma; PP: per protocol; PR: partial response. 
Figure 3: Kaplan–Meier curve of progression-free survival (PP population) and overall survival 
(safety population) 
OS: overall survival; PFS: progression-free survival. 
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Supplementary methods 
Patient Eligibility 
Full eligibility criteria according to the protocol are listed below. 
Inclusion Criteria 
1. Histological diagnosis of DLBCL (de novo or transformed) expressing CD19 by 
immunohistochemistry or flow cytometry analysis (> 30% positivity), based on recent (less 
than 6 months) or new biopsy. 
2.  At least 1 prior specific therapeutic regimen, one of which should have included rituximab 
(patients previously eligible for transplantation: the salvage treatment followed by 
intensification and ASCT will be considered one regimen). 
3.  Either relapsed disease after standard 1st line therapy for aggressive lymphoma - not 
eligible for high dose chemotherapy with stem cell support, or relapsed or refractory disease 
after two lines of therapy one of which could have included ASCT. Relapsed disease is 
defined as progression after a disease free interval of at least 6 months after completion of 
last therapy. Refractory is defined as progression of disease during prior therapy or within 6 
months from its completion. 
4. Available paraffin-embedded tissue should have been collected no longer than 6 months 
prior to first administration of coltuximab ravtansine. Cryo-preserved tissue could not be 
used. If archival material were not available, a Fine Needle Aspiration (FNA) was obtained. 
Archival diagnosis biopsy may be used retrospectively as a complementary material for 
biomarkers analysis. If necessary, a specific informed consent was signed. 
5.  Signed written informed consent. 
Exclusion Criteria 
Patients who met all the inclusion criteria were screened for the following exclusion features: 
1. Primary refractory disease 
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2. Primary mediastinal DLBCL. 
3. Prior chemotherapy or radiotherapy within 4 weeks or radioimmunotherapy within 12 
weeks prior to first administration of SAR3419. Earlier treatment was permitted if 
necessitated by the patient’s medical condition (ie, rapidly progressive disease) following 
discussion with the sponsor. 
4. Toxicities related to prior treatments not having recovered or improved to grade 1 (except 
for alopecia). 
5. Age <18 years. 
6. Performance score (ECOG) 3 or 4. 
7. Evidence of cerebral or meningeal involvement by lymphoma. 
8. Patients without bidimensionally measurable disease by CT scan (defined as presence of at 
least one tumor mass measuring >1.5 x 1.5 cm). 
9. Prior allogeneic bone marrow transplantation.  
10. Prior therapy with anti-CD19 monoclonal antibodies. 
11. Systemic steroids at doses higher than the equivalent dose of 20 mg/day of prednisone 
within 2 weeks prior to first administration of SAR3419. 
12. Known anaphylaxis to study proteins. 
13. Corneal abnormalities at study entry requiring local treatment, recent history of eye surgery, 
history of keratitis or optic neuropathy. 
14. Absolute neutrophil count <1000/μL (no hematologic growth factors in the 4 weeks before 
obtaining this result), or platelet count <75,000/μL. No hematologic limitation in case of 
bone marrow involvement by tumor. 
15. Abnormal liver and kidney function as evidenced by: ASAT or ALAT > 3 x Upper Normal Limit 
(UNL), Total bilirubin > 1.5 x UNL unless Gilbert’s disease, Serum Creatinine 1.5 x UNL and if 
creatinine > UNL and creatinine clearance < 50 mL/min. 
16. Known HIV positivity. 
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17. Active HBV (HBsAg, HBeAg and viral DNA positive, with absence of anti-HBe antibody) or 
HCV infection (presence of circulating anti-HCV antibodies); non-active disease that may 
flare up following the treatment (carriers for HBsAg with presence of HBc antibodies). 
18. Any serious active disease or co-morbid condition which in the opinion of the principle 
investigator will interfere with the safety or the compliance with the study. 
19. Second malignancy other than basal cell or squamous cell carcinoma of the skin or in situ 
carcinoma of the cervix or the breast, unless the tumor was treated with curative intent at 
least 5 years prior to first administration of coltuximab ravtansine. 
20. Unable to comply with scheduled visits or procedures. 
21. Pregnant or breast-feeding women. 
22. Patients with reproductive potential (female and male) who do not agree to use an accepted 
effective method of contraception during the study treatment period and for at least 3 
months following completion of study treatment. 
Dose modifications 
Dose reduction to 40 mg/m2 was permitted in patients who developed grade ≥3 non-
hematologic toxicity but who had achieved clinical benefit (investigator’s assessment), or if ≥2 
toxicity-related dose delays occurred from cycle 2 onwards. If ≥2 dose delays occurred during cycle 
1, or if further dose reductions were required from cycle 2 onwards, the patient was permanently 
withdrawn. 
Ophthalmic assessments 
Examination consisted of assessment of ocular/visual signs and symptoms, slit lamp examination and 
measurement of visual acuity. Schirmer’s test was performed if needed. Patients with any 
ocular/visual symptom (i.e. blurred vision, photophobia) during treatment had these assessments 
repeated at the time of occurrence of the toxicity and then once weekly until resolution. 
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Biomarker assessments 
Tumor biomarkers were evaluated in formalin-fixed, paraffin-embedded (FFPE) tumor tissue 
collected ≤6 months prior to enrolment or from freshly collected biopsies or fine-needle aspirates. 
CD19 was measured at each study site using immunohistochemistry (IHC) or flow cytometry, then 
reassessed by central review using IHC. CD19 expression was assessed through several measures: % 
of cells with positive staining at any intensity; average intensity (0 [no staining], 1+ [weak], 2+ 
[moderate], or 3+ [strong]); % of positive cells at each intensity; and H-score ([% of positive cells at 
intensity 1+]  1 + [% of positive cells at intensity 2+]  2 + [% of positive cells at intensity 3+]  3). 
MYC and BCL2 expression were evaluated in FFPE samples using central IHC. Patients with 
≥40% MYC-positive cells and ≥70% BCL2-positive cells were classified as MYC/BCL2-positive.1 Cell of 
origin was determined using quantitative nuclease protection assay (qNPA) or, if qNPA results were 
missing, by IHC with classification according to the Choi algorithm.2 
Statistical analysis  
The predictive accuracy of CD19 as a biomarker for clinical response (ORR) was assessed using 
sensitivity and specificity measures. The sensitivity and specificity for each candidate value of each 
measure of CD19 expression (using central assessment) were calculated, and a plot of sensitivity 
versus 1-specificity as the threshold varies (receiver operating characteristics [ROC] curve) was 
plotted. The area under the curve (AUC) of the ROC curve was taken as a measure of predictive 
accuracy of the tested biomarker and was interpreted as the probability that a randomly selected 
responder would have a larger value of the biomarker compared to a randomly selected non-
responder (a biomarker is non-informative when AUC is 0 and most informative when AUC is 1). An 
optimal threshold was then determined to define an enrichment signature that minimized the 
Fisher’s exact test p-value for the difference in ORR between patients above and below the 
threshold. A target test profile for each candidate enrichment signature was defined based on three 
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criteria: minimum prevalence for biomarker positivity; minimum negative predictive value 
(proportion of non-responders in the biomarker negative group); and minimum absolute 
improvement in ORR in the biomarker positive group relative to the PP population. 
 
References 
1 Hu S, Xu-Monette ZY, Tzankov A, et al. MYC/BCL2 protein coexpression contributes to the 
inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates 
high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP 
Consortium Program. Blood 2013; 121: 4021–31. 
2 Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse 
large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009; 15: 
5494–502. 
  
6 
 
Supplementary figure 
Supplementary Figure 1. Responses by percentage of CD19-expressing cells at all intensity levels 
CR: complete response; PD: progressive disease; PDd: death from progressive disease before response 
assessments were conducted; PR: partial response; SD: stable disease. 
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Supplementary table. 
Supplementary Table 1. Predictive accuracy of CD19 expression levels as a biomarker for clinical response  
CD19 Population AUC (90% CI) 
Average intensity 0.6 (0.45–0.75) 
Percent positive cells 0.42 (0.26–0.58) 
Percent positive cells at intensity 1+ 0.56 (0.4–0.72) 
Percent positive cells at intensity 2+ 0.53 (0.37–0.69) 
Percent positive cells at intensity 3+ 0.65 (0.49–0.81) 
H-score 0.57 (0.41–0.73) 
AUC, area under the curve 
 
 
 
